Mylan Inc. announced today that it has signed a license and supply agreement with NATCO Pharma Ltd. (NATCO) for NATCO's glatiramer acetate pre-filled syringes, a generic version of Teva's Copaxone(R), which is used to treat multiple sclerosis. The agreement grants Mylan exclusive distribution rights in the United States and all major markets in Europe, Australia, New Zealand, Japan and Canada and includes an option to expand into additional territories.
NATCO has commercialized successfully its glatiramer acetate product in India and the Ukraine. Teva has reported that worldwide sales of Copaxone were more than $1.7 billion in 2007.
The details can be read here.
No comments:
Post a Comment